Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease

IJU Case Reports

article

Daiji Takamoto¹  Hajime Sasaki¹  Hiroshi Kataoka⁴  Fumihiro Kodama⁵  Haruka Higuchi¹  Tetsuo Hirano¹  Yusuke Takada¹  Shigeru Harada¹  Hiroshi Harada¹  Hiroshi Tanaka¹ 

[1] Department of Kidney Transplant Surgery, Sapporo City General Hospital;These authors contributed equally to the manuscript.;Contribution: Conceptualization;Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital;Department of Infectious Diseases, Sapporo City General Hospital;Contribution: Supervision;Department of Urology, Sapporo City General Hospital

关键词: COVID-19;    cytokine release syndrome;    dexamethasone;    kidney transplant recipient;    tocilizumab;   

DOI  :  10.1002/iju5.12492

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

Introduction Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for such patients have not been established. Here, we describe two cases of successful immunomodulation in Japanese kidney transplant recipients with cytokine release syndrome following coronavirus disease. Case presentation Two patients who had been receiving long-term immunosuppressant therapy developed coronavirus disease-associated pneumonia caused by cytokine release syndrome, following immunosuppressant dosage reduction. However, they recovered immediately after administration of tocilizumab with or without dexamethasone. Conclusion The immunosuppressant dosage should be reduced to restore host immunity; however, immunomodulation should be considered in cases of suspected cytokine release syndrome.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND